Effects of novel, high affinity glycine transport inhibitors on frontostriatal dopamine release in a rodent model of schizophrenia.

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
Andrea BallaDaniel C Javitt

Abstract

Dopaminergic hyperactivity within frontostriatal brain systems is a key feature of schizophrenia, and an objective neural correlate of positive schizophrenia symptoms. N-methyl-d-aspartate (NMDA) receptors are known to play a prominent role in regulation of frontostriatal dopamine release. Furthermore, disturbances in glutamatergic function are increasingly being linked to pathophysiology of both positive and negative symptoms of schizophrenia. Prior studies have demonstrated that subchronic continuous administration of the NMDA antagonist phencyclidine (PCP) induces schizophrenia-like hyper-reactivity of frontostriatal dopamine release to amphetamine (AMPH) in rodents, and that effects were reversed by glycine and the prototypic glycine transport inhibitor (GTI) NFPS. The present study investigates effectiveness of the novel, high affinity and well tolerated GTIs, R231857, R231860 and Org29335, to reverse schizophrenia-like enhancement of AMPH-induced DA release, along with effects of the partial glycine-site agonist d-cycloserine. As previously, PCP had no significant effect on basal DA levels, but significantly enhanced AMPH-induced DA release in prefrontal cortex. All GTIs tested, as well as d-cycloserine, significantly red...Continue Reading

References

Oct 1, 1991·The American Journal of Psychiatry·D C Javitt, S R Zukin
Sep 1, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·D C JavittA Lajtha
Jan 1, 1996·Harvard Review of Psychiatry·J T Coyle
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·R BergeronR W Greene
Jun 27, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·A BallaD C Javitt
Jul 2, 2002·Archives of General Psychiatry·John H KrystalBita Moghaddam
Dec 24, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Andrea BallaDaniel C Javitt
Apr 2, 2003·Pharmacology, Biochemistry, and Behavior·Laszlo G HarsingGyorgy Levay
Oct 16, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Daniel C JavittHenry Sershen
Apr 21, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hideo TsukadaEdward F Domino
Jun 16, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ronan DepoortèreBernard Scatton
Nov 14, 2006·Current Opinion in Pharmacology·Lars V KristiansenJames H Meador-Woodruff
Jun 22, 2007·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Yukitaka MoritaShigetoshi Kuroda
Jul 31, 2007·Biological Psychiatry·Hsien-Yuan LaneGuochuan E Tsai
Sep 6, 2007·Proceedings of the National Academy of Sciences of the United States of America·Lucila KargiemanFrancesc Artigas
Jan 7, 2009·Archives of General Psychiatry·Oliver D HowesPaul M Grasby
Mar 14, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Philipp SingerBenjamin K Yee
Mar 28, 2009·Schizophrenia Bulletin·Oliver D Howes, Shitij Kapur
May 5, 2009·Trends in Neurosciences·Christoph KellendonkEric R Kandel
Sep 18, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Denis BoulayGuy Griebel
Feb 27, 2010·Neuroreport·Brooke M RobertsStacy A Castner
Jul 7, 2010·Archives of General Psychiatry·Paolo Fusar-PoliPhilip K McGuire
Oct 1, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bita Moghaddam, Daniel Javitt
Oct 1, 2011·Science Translational Medicine·Daniel C JavittChi-Ming Lee
Nov 25, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Deepak Cyril D'SouzaJacques Schipper

❮ Previous
Next ❯

Citations

Oct 15, 2014·Neuropharmacology·Mauro Cunha Xavier PintoRenato Santiago Gomez
May 14, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Mark J MillanWilliam P Horan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis is a form of of brain inflammation due to antibodies against NMDA receptors. Discover the latest research on anti-NMDA receptor encephalitis here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.